-transparent.png){kind=logo}
Two mouse monoclonal antibodies against the human osteogenic sarcoma 791T were examined for their capacity to exert complement-dependent cytotoxicity against a panel of human tumour cell lines. Cytotoxicity was most evident against the immunizing tumour 791T although significant reactivity was directed against other osteogenic sarcomas. In admixture, the 2 antibodies displayed synergism in their cytotoxicity although this was only demonstrable with defined ranges of antibody concentration. The cytotoxicity of these antibodies was dependent upon the use of rabbit serum as complement and no tumour-cell lysis was produced using human, guinea-pig or mouse serum complement. The more potent cytotoxic antibody failed to modify the outgrowth of 791T tumour xenografts in immunodeprived mice even though localization of antibody at the tumour site has been demonstrated (Pimm et al., 1982).
M R Price, and
M V Pimm, and
R W Baldwin
January 1988,
Immunology,
M R Price, and
M V Pimm, and
R W Baldwin
August 1991,
Zhonghua wai ke za zhi [Chinese journal of surgery],
M R Price, and
M V Pimm, and
R W Baldwin
June 1981,
International journal of cancer,
M R Price, and
M V Pimm, and
R W Baldwin
January 1985,
Biomedica biochimica acta,
M R Price, and
M V Pimm, and
R W Baldwin
February 1990,
Journal of clinical & laboratory immunology,
M R Price, and
M V Pimm, and
R W Baldwin
October 2013,
British journal of haematology,
M R Price, and
M V Pimm, and
R W Baldwin
January 2002,
Human immunology,
M R Price, and
M V Pimm, and
R W Baldwin
December 2012,
Medical oncology (Northwood, London, England),
M R Price, and
M V Pimm, and
R W Baldwin
March 1997,
Journal of immunological methods,
M R Price, and
M V Pimm, and
R W Baldwin
May 1984,
Cancer research,
